GH Research PLC is a clinical-stage biopharmaceutical company developing novel mebufotenin therapies to treat treatment-resistant depression and other psychiatric and neurological disorders. The company's lead product candidate, GH001, is an inhalable mebufotenin formulation designed to deliver rapid antidepressant effects, while GH002 is an intravenous formulation in earlier development. GH Research targets patients with treatment-resistant depression who have failed multiple existing antidepressant therapies, a large patient population with substantial unmet medical needs and high healthcare costs, and plans to generate revenue through regulatory approval and commercialization of its product candidates in the United States and major European markets, leveraging internal sales capabilities or selective partnership arrangements.